Viral Hepatitis Prevention and Control
Active
- Assistance listing
- 93.270
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Grant awards
- 339 $333,869,947 in federal obligations
Program facts
- Also known as
- Integrated Viral Hepatitis Surveillance and Prevention
- Assistance type
-
- Cooperative Agreement
- Treasury accounts
-
- 75-0950-0-1-550
- 09-2950-2-0-131
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The Centers for Disease Control and Prevention (CDC) is awarding Cooperative Agreements under the Viral Hepatitis Prevention and Control program (CFDA 93.270) to fund integrated surveillance and prevention programs for hepatitis A, B, and C in states and large cities, with the most recent grant award dated September 30, 2021.
The program funds surveillance, outbreak response, and prevention activities targeting viral hepatitis elimination. Recipients conduct disease surveillance for acute hepatitis A, acute and chronic hepatitis B, and acute, chronic, and perinatal hepatitis C; develop and implement viral hepatitis outbreak response plans; establish jurisdictional frameworks for outbreak detection; and develop state-level viral hepatitis elimination plans. Prevention work includes increasing hepatitis B and C testing in high-impact settings such as syringe services programs, substance use disorder treatment centers, correctional facilities, and emergency departments; linking diagnosed individuals to care and treatment; training healthcare providers in hepatitis diagnosis and treatment; and improving access to harm reduction services for people who inject drugs. Recipients may not use funds for clinical care or, generally, for furniture or equipment purchase. Recipients must perform a substantial programmatic role and not serve merely as a conduit for another party.
Funding is exclusively through the CDC, distributed as Cooperative Agreements (100 percent of the 339 awards in the portfolio). The program has obligated $333.9 million in federal dollars across the portfolio since 2007. Recent annual award activity shows variability, with 10 awards in 2013, 64 in 2016, and 32 in 2021. Typical recent awards range from approximately $965 thousand to $5.2 million; representative recipients include state health departments in Florida ($4.9 million), Massachusetts ($4.2 million), West Virginia ($4.7 million), Iowa ($5.2 million), and non-state organizations such as the University of Washington Hepatitis Training Center ($1.9 million for online professional education in hepatitis B and C screening and management) and WebMD Health Corp. ($1.6 million for Medscape-based clinician education targeting healthcare providers serving priority hepatitis populations).
Two solicitations are currently active. CDC-RFA-PS-27-0009 (Integrated Viral Hepatitis Surveillance, Testing, Treatment, and Prevention Programs for Health Departments), posted June 9, 2026, funds required components in outbreak response, surveillance, planning and partnerships, with optional components in testing and treatment and perinatal hepatitis C programming; eligible applicants are state health departments, territories, and large cities. CDC-RFA-PS-27-0011 (National Viral Hepatitis Education, Awareness, and Capacity Building for Communities and Providers), posted July 9, 2026, supports two separate components—community education and coalition building, and professional healthcare provider training—with broad eligibility across nonprofit, for-profit, and government entities.
Objective and description
- Objective
Program activities support integrated viral hepatitis surveillance and prevention programs in states and large cities in the United States. Key strategies include viral hepatitis outbreak planning and response; and surveillance for acute hepatitis A,
- Description
Funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers. Recipients may not use funds for clinical care. Recipients may not generally use funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget. The recipient must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award in another party or provider who is eligible.
Eligibility
- Applicant eligibility
Dependent upon the individual NOFO, eligibility may range from open competition, limited competition, single-source, domestic and/or international in accordance with the authorizing legislation.
- Beneficiary eligibility
The general public will benefit from the objectives of this program as well society from the savings realized from treating those that are infected with viral hepatitis.
- Uses of assistance
Funds may be used for costs associated with establishing and maintaining a prevention and control program directed towards prevention of viral hepatitis infections and their manifestations. Recipients may only expend funds for reasonable policies, systems and program purposes including personnel, travel, supplies and services, such as reducing transmission of HAV, HBV and HCV, preventing and delaying the progress of chronic infection, as well as educating and training of the general public and health care providers.
- Length and time phasing of assistance
Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient.
How to apply
- Criteria for selecting proposals
Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC.
- Award procedure
After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any.
- Renewals
Cooperative agreement period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
Grant opportunities
Show all 13
Grant awards
Latest 10 of 339 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | World Health Organization | $53,915,372 | 16% |
| 2 | Florida Department Of Health | $13,238,850 | 4% |
| 3 | Massachusetts Department Of Public Health | $10,601,229 | 3% |
| 4 | Health Research, Inc. | $8,478,297 | 3% |
| 5 | City Of New York | $7,930,806 | 2% |
| 6 | West Virginia Department Of Health And Human Resources | $7,904,169 | 2% |
| 7 | State Of Georgia Department Of Public Health | $7,792,124 | 2% |
| 8 | Iowa Department Of Public Health | $7,532,067 | 2% |
| 9 | Oregon Health Authority-Public Health | $7,173,666 | 2% |
| 10 | Louisiana Department Of Health | $6,811,672 | 2% |
10 of 111 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $3,406,139 |
| FY2025 | $14,538,868 |
| FY2024 | $29,152,606 |
| FY2023 | $34,155,273 |
| FY2022 | $40,623,881 |
| FY2021 | $23,298,945 |
| FY2020 | $42,937,550 |
| FY2019 | $38,715,017 |
| FY2018 | $14,313,274 |
| FY2017 | $16,033,735 |
| FY2016 | $16,215,547 |
| FY2015 | $15,978,421 |
| FY2014 | $15,829,802 |
| FY2013 | $16,700,221 |
| FY2012 | $8,436,714 |
| FY2011 | $5,323,921 |
Show all 16
Quick answers
What is Assistance Listing 93.270?
Assistance Listing 93.270 is Viral Hepatitis Prevention and Control, a federal grant program run by Centers for Disease Control and Prevention (Department of Health and Human Services).
What is the CFDA number for Viral Hepatitis Prevention and Control?
Its CFDA number is 93.270: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.270 awarded?
339 grant awards under 93.270 have obligated $333,869,947 in federal funds to 111 recipients.
Who receives the most funding from 93.270?
The recipients obligated the most under Viral Hepatitis Prevention and Control are World Health Organization ($53,915,372), Florida Department Of Health ($13,238,850) and Massachusetts Department Of Public Health ($10,601,229).
How much did 93.270 obligate in fiscal year 2025?
Grants under 93.270 obligated $14,538,868 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.270?
2 listed opportunities under 93.270 are open or forecasted. The latest, National Viral Hepatitis Education, Awareness, and Capacity Building for Communities and Providers, was posted on July 9, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program